Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Malaria drug resistance confirmed in ethiopia: study raises alarm

NCT ID NCT07527182

Knowledge-focused Sponsor: Didier Menard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether the malaria parasite in Ethiopia is becoming resistant to artemisinin, the main drug used to treat it. Researchers tested 277 patients across five sites, checking if parasites were still in the blood three days after treatment and looking for a specific genetic marker. The goal was to confirm if drug resistance is present, which could affect how malaria is treated in the region.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

277 people

The number who actually took part.

Started

May 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 6 months * Microscopically confirmed uncomplicated Plasmodium falciparum monoinfection * Axillary temperature ≥ 37.5°C or history of fever in the past 24 hours * Ability to take oral medication * Written informed consent from patient or parent/guardian * Residence in the study area with intention to remain during follow-up Exclusion Criteria: * Severe or complicated malaria (WHO criteria) * Mixed Plasmodium infection * Pregnancy or breastfeeding * Known hypersensitivity to artemether-lumefantrine * Antimalarial treatment in the 4 weeks prior to enrollment * Severe malnutrition * Concomitant febrile illness other than malaria requiring systemic treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artemisinin-resistant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artemisinin-resistant Drug resistance Ethiopia Malaria (plasmodium falciparum)

Contacts and locations

Locations

  • Bako Health Center

    Bako, Ethiopia

  • Mehoni Health Center

    Mersa, Tigray, Ethiopia

  • Metahara Health Center

    Metehara, Ethiopia

  • Rama Health Center

    Rama, Ethiopia

  • Workamba Health Center

    Kechemo, Ethiopia

More trials for these conditions

Other studies related to the condition(s) this trial covers.